Compare AbbVie Inc (ABBV) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Yum China Holdings Inc — how do they compare? AbbVie Inc trades at $253.63 (market cap $449.91B), while Yum China Holdings Inc trades at $42.77 (market cap $14.58B). The key difference: AbbVie Inc is far larger — about 30.9× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| ABBV | YUMC | |
|---|---|---|
Market Cap | $449.91B | $14.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $57.95 |
52-Week Low | $184.85 | $40.18 |
Enterprise Value | $513.38B | $15.47B |
Dividend Yield | 2.72% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
YUMC trades at $42.22, up 1.25% today, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.87 exceeding the $0.854 estimate. Revenue grew to $11.80B in 2025, and the stock trades at a P/E of 16.28. Recent news highlights YUMC's acquisition of Pizza Hut brand rights in mainland China and a $512 million share repurchase plan.
The outlook is positive given consistent earnings outperformance, strategic brand control expansion, and shareholder returns. Risks include China's competitive consumer market and economic sensitivity. Analyst consensus is strongly bullish with 14 buys and no sells, supporting a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
